Leukemia Therapy

Novel regimen effective for JMML patients without stem-cell donors

Published in Blood Weekly, March 11th, 2004

A novel treatment regimen is effective for JMML patients without suitable stem-cell donors.

According to recent research from South Korea, "effective treatment for juvenile myelomonocytic leukemia (JMML) patients lacking access to stem-cell transplantation remains unavailable."

H.J. Kang and coauthors at Seoul National University described "a promising result obtained with novel regimen comprised of a combination of chemotherapy and differentiation therapy."

"Five patients diagnosed as JMML were treated with a standard regimen (cytosine arabinoside (Ara-C) 100 mg/m² per day continuous infusion (days 0-6), etoposide 100...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-03-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry